Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312294 | 0.77 | EGFR (0.38) | EGFR | |
| SCHEMBL9572676 | 0.75 | EGFR (0.33) | EGFR | |
| SCHEMBL7702472 | 0.75 | RPS6KA5 (0.35) | EGFR | |
| SCHEMBL2141779 | 0.75 | EGFR (0.34) | EGFR | |
| SCHEMBL1586125 | 0.75 | EGFR (0.33) | EGFR | |
| SCHEMBL1021063 | 0.75 | EGFR (0.33) | EGFR | |
| SCHEMBL7948683 | 0.75 | EGFR (0.33) | EGFR | |
| SCHEMBL2011130 | 0.75 | EGFR (0.33) | EGFR | |
| SCHEMBL9652879 | 0.75 | EGFR (0.33) | EGFR | |
| SCHEMBL277594 | 0.75 | EGFR (0.33) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541569-B2 | Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA | CHEMGENES CORPORATION (US) | 2013-09-24 | — | — | US | claimed |
| EP-2560982-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | Chemgenes Corporation (US) | 2013-02-27 | — | — | EP | claimed |
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | CHEMGENES CORPORATION | 2012-06-14 | — | — | US | claimed |
| EP-2398815-A2 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | Chemgenes Corporation (US) | 2011-12-28 | — | — | EP | claimed |
| WO-2011103468-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | CHEMGENES CORPORATION (US) | 2011-08-25 | — | — | WO | claimed |
| US-20110137010-A1 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, EFFICIENT RNA SYNTHESIS AND CONVENIENT INTRODUCTION OF 3'-END LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA | CHEMGENES CORPORATION (US) | 2011-06-09 | — | — | US | claimed |
| WO-2010096201-A2 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | CHEMGENES CORPORATION (US) | 2010-08-26 | — | — | WO | claimed |
| EP-1383925-B1 | METHOD FOR LABELLING AND FRAGMENTING DNA | BIO MERIEUX (FR) | 2006-09-20 | — | — | EP | claimed |
| US-7060441-B2 | Method for fragmenting and labeling DNA involving abasic sites and phosphate labeling | BIOMERIEUX (FR) | 2006-06-13 | — | — | US | claimed |
| US-20030143555-A1 | Fragmenting the DNA by creating at least one abasic site on DNA, attaching a marker to one of the fragments by means of labeling reagent which is covalently and predominantly coupling to the phosphate of the fragment | BIO MERIEUX (FR) | 2003-07-31 | — | — | US | claimed |
| CN-112533607-B | TLR7 agonists | 普利缪尼治疗学股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-11578073-B2 | Xanthine analogs as potent anti-West Nile viral agents | SOUTHERN RESEARCH INSTITUTE (US) | 2023-02-14 | — | — | US | disclosed |
| CN-112533607-A | TLR7 agonists | 普利缪尼治疗学股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20200399271-A1 | XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS | OREGON HEALTH AND SCIENCE UNIVERSITY | 2020-12-24 | — | — | US | disclosed |
| US-8541569-B2 | Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA | CHEMGENES CORPORATION (US) | 2013-09-24 | — | — | US | disclosed |
| US-4855304-A | INHIBITION OF PLANT VIRUS REPLICATION | REPLIGEN CORPORATION (US) | 1989-08-08 | — | — | US | disclosed |
| EP-0175325-B1 | NEW 8-SUBSTITUTED NUCLEOSIDE AND PURINE DERIVATIVES, THE PROCESS FOR THE PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pierrel S.p.A. (IT) | 1989-03-15 | — | — | EP | disclosed |
| US-4774325-A | ANTILIPEMIC AGENTS | PIERREL SPA (IT) | 1988-09-27 | — | — | US | disclosed |
| EP-0192315-A1 | Treatment of plant viruses | REPLIGEN CORPORATION (US) | 1986-08-27 | — | — | EP | disclosed |
| EP-0175325-A2 | New 8-substituted nucleoside and purine derivatives, the process for the preparation thereof and the pharmaceutical compositions containing them | Pierrel S.p.A. (IT) | 1986-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | TYMP, MTAP, GART | ADORA2A 170/4885ADORA1 122/4885EGFR 2484/4885 |
| US-20200399271-A1 | XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS | XDH, PNP, MAVS | ADORA2A 13/4885ADORA1 83/4885EGFR 4881/4885 |
| US-11578073-B2 | Xanthine analogs as potent anti-West Nile viral agents | XDH, PNP, MAVS | ADORA2A 13/4885ADORA1 83/4885EGFR 4881/4885 |
| US-20110137010-A1 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, EFFICIENT RNA SYNTHESIS AND CONVENIENT INTRODUCTION OF 3'-END LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA | NSUN3, RNGTT, NOP2 | ADORA2A 1238/4885ADORA1 759/4885EGFR 4170/4885 |
| US-20030143555-A1 | Fragmenting the DNA by creating at least one abasic site on DNA, attaching a marker to one of the fragments by means of labeling reagent which is covalently and predominantly coupling to the phosphate of the fragment | FEN1, DNMT1, UNG | ADORA2A 1837/4885ADORA1 770/4885EGFR 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.